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                                          INTRODUCTION 
             Portal hypertension (PHT) is an important complication of chronic 
liver disease of any etiology . One of the most significant clinical 
consequences of portal hypertension in cirrhotic patients is the development 
of gastroesophageal varices, portal hypertensive gastropathy (PHG) and 
gastric antral vascular ectasia (GAVE). These vascular lesions are 
considered to be a significant source of upper gastrointestinal bleeding in 
patients with portal hypertension. 
   
           Over the past few years, it has been observed that not only the 
stomach but the entire gastrointestinal tract, with its venous drainage through 
the portal venous system, is involved in patients with portal hypertension. 
Involvement of the duodenum , the small intestine , and the colon  have all 
been described. Only a few studies, however, have investigated the colon in 
patients with portal hypertension.  
 
           Colorectal mucosal lesions in patients with portal hypertension is 
termed  as portal hypertensive colopathy (PHC). These are thought to be 
important causes of lower gastrointestinal hemorrhage, although the clinical 
importance of these lesions in patients with portal hypertension  is not well 
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established. The features of PHC are not well defined but include multiple 
vascular appearing lesions ( telangiectasias, cherry red spots and 
angiodysplasia like lesions), colitis- like abnormalities ( granularity, 
erythema, edema, friability ), colorectal varices, or a combination of these 
findings. The diagnostic criteria and clinical significance of this condition is 
confusing. This may be partially due to imprecise terminology, lack of 
uniform endoscopic descriptions, interobserver variability and the absence of 
distinctive histopathologic features.  
                       The effect of endoscopic sclerotherapy (EST) as well as 
endoscopic variceal band ligation (EVL), on PHG is well known. In most 
studies an increased incidence of PHG has been noted in patients who have 
undergone EST and EVL. There are few studies  which  suggest that variceal 
obliteration may result in an increase in the incidence of anorectal varices 
and portal hypertensive colopathy. In more recent years, EVL has virtually 
replaced EST as the treatment option for esophageal varices. However, there 
are very few studies  which have  investigated the effect of EVL on the 
colonic mucosa in patients with portal hypertension.   
                        In this study, we evaluated the prevalence of colonic mucosal 
changes in patients with chronic liver disease and portal hypertension before 
and after endoscopic variceal obliteration  and its clinical significance 
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                                  REVIEW OF LITERATURE 
             Cirrhosis is a gradually developing, chronic disease of the liver. It is 
the irreversible consequence and final stage of various liver disease of 
different etiology or the result of long term exposure to noxious agents. 
Aretaeus (2nd century AD) coined the term “skirros”, because he thought that 
inflammation of the liver led to its hardening (skirros). 
             The first accurate report on cirrhosis was given by R.T.H. Laennec 
(1819). Because of the yellow colour of the liver (kirros), he coined the term 
cirrhosis. The morphological changes depend on the cause and stage of 
cirrhosis. Accordingly, there is a wide spectrum of morphological findings 
and clinical symptoms. The variation of this disease range from symptom 
free conditions, non characteristic complaints and different laboratory 
findings through to life threatening  complications. 
            Cirrhosis of liver can be classified either etiologically or 
morphologically. The etiological classification is based on the underlying 
cause which includes alcohol, hepatitis B and hepatitis C infections, 
metabolic disorders like Wilson disease, nonalcoholic fatty liver disease and 
and also due to autoimmune hepatitis. When no cause is found it is called as 
cryptogenic cirrhosis. Morphological classification is based on the size of 
the nodules. It could be micronodular if the nodules are less than 3mm, 
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macronodular if they are more than 3mm and mixed type if both are found. 
The mixed type is the transition form from micronodular to macronodular 
cirrhosis. 
            Cirrhosis of the liver is a disease found all over the world, affecting 
all races, age groups and both sexes. The increasing mortality rate runs 
parallel to regional alcohol consumption. This correlation between alcohol 
consumption and mortality as well as morbidity due to cirrhosis applies 
equally to men and women. The slight decrease in mortality in some 
countries observed during the past 10 -15 years may be due to more effective 
prophylaxis and improved treatment options for complications.  
             Portal hypertension is one of the salient features of cirrhosis. 
Cirrhosis of the liver accounts for approximately 90% of cases of portal 
hypertension. 
                           
                              PORTAL HYPERTENSION  
Definition: A clinical syndrome defined by a pathologic increase in the 
portal venous pressure, in which the portal pressure gradient is >5 mmHg 
(difference between the pressure of the portal vein and that of the inferior 
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vena cava). The portal vein is 5- 8 cm long with a diameter of 1.2 + 0.2 (or 
0.97) cm 1. 
 
Classification  of Portal Hypertension 
        Portal hypertension is classified according to the localization of the 
flow resistance. Increases in pressure in the portal vascular system are 
rapidly transferred to the preceding vascular sections, since the portal vein 
does not possess any venous valves. Depending on whether the localization 
lies before, within or beyond the liver, the portal hypertension is broken 
down into prehepatic, intrahepatic and posthepatic blocks. The intrahepatic 
form is further subdivided into a presinusoidal, sinusoidal and postsinusoidal 
rise in resistance.  
NON-PARENCHYMATOUS PORTAL HYPERTENSION 
1. PREHEPATIC PORTAL HYPERTENSION 
2. INTRAHEPATIC PORTAL HYPERTENSION 
 A. PRESINUSOIDAL BLOCK 
PARENCHYMATOUS PORTAL HYPERTENSION 
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 B. SINUSOIDAL BLOCK 
 C. POSTSINUSOIDAL BLOCK                                                                   
3. POSTHEPATIC PORTAL HYPERTENSION 
  
 Pathophysiology of Portal Hypertension 
                       Portal Pressure Gradient (PPG) is the result of the interaction 
between the portal blood flow and the vascular resistance to the flow. This 
relationship is defined  by Ohm's law in the following equation: 
ΔP = Q × R 
        in which ΔP is the PPG (the difference between the portal pressure and 
the IVC pressure), Q is the blood flow within the entire portal venous system 
(which in portal hypertension includes the portal–systemic collaterals), and 
R is the vascular resistance of the entire portal venous system. It follows that 
portal pressure may be increased by an increase in portal blood flow, an 
increase in vascular resistance, or a combination of both 2. It is well 
established that in cirrhosis, the primary factor leading to portal hypertension 
is an increased resistance to portal blood flow. An 
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increased portal venous inflow maintains and exacerbates portal 
hypertension. This component of increased blood flow becomes especially 
important in advanced stages. 
Increased Vascular Resistance to Portal Blood Flow 
            Increased resistance to portal blood flow is the primary factor in the 
pathophysiology of portal hypertension and may occur at any site within the 
portal venous system. In cirrhosis, increased intrahepatic vascular resistance 
is thought to be mainly in the hepatic sinusoids 3. For many years, the 
increased intrahepatic vascular resistance was thought to be a fixed, 
mechanical consequence of architectural distortion of the hepatic 
microcirculation by fibrosis, scarring, and nodules. In addition, careful 
pathologic studies have suggested that thrombosis of medium and large 
portal and hepatic veins is a frequent occurrence in cirrhosis and that these 
events may be important in causing a progression of cirrhosis and worsening 
of portal hypertension 4 . However, recent studies have demonstrated that in 
addition to the increased resistance caused by the morphologic changes of 
chronic liver diseases, a dynamic component of increased resistance is 
present that represents active contraction of the contractile elements in the 
liver. These elements constrict in a reversible and graded manner in response 
to several agonists, thereby further increasing the intrahepatic resistance 5. It 
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has been claimed that this dynamic component may represent up to 40% of 
the increase in intrahepatic vascular resistance. 
              The contractile elements of the hepatic vascular bed are located at a 
sinusoidal level and at extrasinusoidal sites 6,7,8. They include smooth muscle 
cells of the intrahepatic vasculature (i.e., small portal venules in portal areas) 
6; activated hepatic stellate cells, which are located in the perisinusoidal 
space of Disse and have extensions that wrap around the sinusoids7; and 
hepatic myofibroblasts, which are abundant in the fibrous tissue in and 
around cirrhotic nodules. Contraction of hepatic myofibroblasts may 
increase intrahepatic resistance by compressing venous shunts in the fibrous 
septa. It is now clear that vasoactive mediators, either vasoconstrictors or 
vasodilators, modulate intrahepatic vascular resistance in both the healthy 
and the cirrhotic liver. An increased production of vasoconstrictors and an 
exaggerated response of the hepatic vascular bed to these agents, as well as 
an insufficient release of vasodilators, together with an impaired 
vasodilatory response of the hepatic vascular bed, are the mechanisms that 
have been implicated in the pathogenesis of the dynamic component of the 
increased intrahepatic resistance of the cirrhotic liver 3. 
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Increased Production of Vasoconstrictors  
Endothelins :  Endothelins (ETs) are a family of homologous 21 amino acid 
vasoactive peptides (ET-1, ET-2, and ET-3) that are thought to play a major 
role in modulating hepatic vascular tone in cirrhosis 9. The biologic 
properties of ETs are mediated essentially by two major ET receptors, ET-A 
and ET-B. The ET-A receptor shows a high affinity for ET-1 and mediates 
constriction; the ET-B receptor has equal affinity for ET-1 and ET-3. 
Activation of  ET-B receptors located on the vascular smooth muscle cells 
promotes vasoconstriction, whereas activation of ET-B receptors located on 
endothelial cells promotes vasodilatation, which is mediated by enhanced 
nitric oxide (NO) and prostacyclin produced by the endothelial cell. Patients 
with liver cirrhosis have increased circulating plasma levels of ET-1 and ET-
3 10. Endothelial cells, hepatic stellate cells (in their activated phenotype), 
and bile duct epithelial cells are the major intrahepatic sources of ET-1. ET-
1 increases portal perfusion pressure by increasing intrahepatic resistance in 
isolated, perfused normal livers and carbon tetrachloride–induced cirrhotic 
livers. Although some experimental studies reported a slight reduction of 
portal pressure in cirrhotic animals after the administration of ET antagonists 
11, 12, this was not confirmed by other studies 13. Therefore, the role of ETs in 
increasing the vascular tone in cirrhosis remains unsettled.  
10 
 
         Other vasoconstrictive factors are involved in the regulation of hepatic 
vascular tone. Studies in perfused cirrhotic livers have shown that 
norepinephrine, angiotensin II, and vasopressin, three circulating vasoactive 
factors whose levels are usually elevated in cirrhosis, increase intrahepatic 
vascular resistance 14,15.  
Endothelial Dysfunction in Cirrhosis 
             In normal conditions, the endothelium is able to generate vasodilator 
stimuli in response to increases in blood volume, blood pressure, or 
vasoconstrictor agents in an attempt to prevent or attenuate the concomitant 
increase in pressure. In several pathologic conditions there is an impairment 
in this endothelium-dependent vasodilatation, called endothelial dysfunction 
16,17. The hepatic vascular bed of cirrhotic livers also exhibit endothelial 
dysfunction 18. Indeed, studies performed both in patients with cirrhosis and 
in experimental models have shown that, contrary to what happens in normal 
livers, the cirrhotic liver cannot accommodate the increased portal blood 
flow caused by the postprandial hyperemia, which determinesss an abrupt 
postprandial increase in portal pressure 19. This is important because such 
repeated brisk increases in portal pressure and portal– collateral blood flow 
in response to meals and other physiologic stimuli are thought to be a major 
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determinant of the progressive dilatation of the varices in patients with 
cirrhosis 3.  
Insufficient Release of Hepatic Vasodilators 
Nitric oxide :  The role of NO in modulating intrahepatic vascular resistance 
is a subject of considerable interest. NO is a powerful endogenous 
vasodilator generated in several tissues by NO synthases from the amino 
acid L-arginine. It is the natural ligand for soluble guanylate cyclase and is 
responsible for an increase in the levels of cyclic GMP, the final agent 
responsible for the relaxation of the vascular wall through the extrusion of 
cytosolic Ca2+. NO blockade has been shown to increase portal perfusion 
pressure in isolated perfused rat livers. In addition, the hepatic response to 
norepinephrine is markedly enhanced after NO inhibition, a finding that 
further suggests a role for NO in modulating hepatic vascular tone in normal 
conditions 20. In the cirrhotic liver, the synthesis of NO is insufficient to 
compensate for the activation of vasoconstrictor systems frequently 
associated with cirrhosis. This occurs despite a normal expression of 
endothelial nitric oxide synthase (eNOS) mRNA and normal levels of eNOS 
protein 18,21. The decreased activity of hepatic eNOS in cirrhosis is due in 
part to increased expression of caveolin 22. This insufficient hepatic NO 
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generation plays a major role in increasing intrahepatic vascular resistance in 
cirrhosis, thereby worsening portal hypertension.  
Carbon monoxide :  A role for carbon monoxide (CO), a by-product of 
heme group oxidation by heme oxygenases (HOs), as an important 
modulator of intrahepatic vascular tone has been suggested. CO, although 
less potent than NO, also activates guanylate cyclase and thereby promotes 
smooth  relaxation. The inhibition of CO production increases portal 
resistance in normal livers 23. Heme oxidation is catalyzed by two different 
enzymes, HO-1 and HO-2. In normal conditions, CO is produced in the liver 
by the constitutive isoform (or HO-2).However, in several stress conditions, 
such as endotoxemia and hemorrhagic shock, the inducible isoform (or HO-
1) is formed. In this situation, the inhibition of HOs with specific agents 
leads to a much greater increase in portal–hepatic resistance than is seen in 
normal, unstimulated livers 24. In addition, there is a complex interaction 
between the NO and CO systems. NO has been shown to induce HO-1 
expression and, therefore, CO synthesis. On the other hand, CO may inhibit 
the NO-mediated production of cyclic guanylate cyclase monophosphate. 
Therefore, an increased expression of HO-1 in cirrhosis suggests that CO 
may play a role in the hepatic circulatory disturbances found in liver 
cirrhosis. 
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Splanchnic Vasodilatation 
           An increased portal venous inflow is characteristically observed in 
advanced stages of  portal hypertension and is the result of marked arteriolar 
dilatation in the splanchnic organs draining into the portal vein. The 
increased blood flow contributes to the portal hypertensive syndrome 3. 
Different mechanisms have been suggested to explain the observed 
hemodynamic abnormality, which likely represents a multifactorial 
phenomenon involving neurogenic, humoral, and local mechanisms. Initial 
studies focused on the potential role of increased levels of circulating 
vasodilators. Many candidate substances were proposed, most of them being 
vasodilators of splanchnic origin that undergo hepatic metabolism and 
accumulate in the systemic circulation when hepatic uptake is reduced in 
liver disease or during portosystemic shunting. 
Glucagon :   Glucagon is probably the humoral vasodilator for which most 
evidence has been accumulated to indicate a significant role for it in 
splanchnic hyperemia and portal hypertension. Many studies have 
demonstrated that plasma glucagon levels are elevated in patients with 
cirrhosis and experimental models of portal hypertension. 
Hyperglucagonemia  results, in part, from a decreased hepatic clearance of 
glucagon, but more importantly from an increased secretion of glucagon by 
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pancreatic α cells 25. The support for a role of glucagon in modulating 
splanchnic blood flow comes from physiologic studies showing that in rats 
with experimental portal hypertension, normalizing circulating glucagon 
levels by administering glucagon antibodies or infusing somatostatin 
partially reverses the increase in splanchnic blood flow, a response that can 
be specifically blocked by the concomitant infusion of glucagon 26,27. 
Conversely, other studies have shown that increasing circulating glucagon 
levels in normal rats to values similar to those observed in portal 
hypertension causes a significant increase in splanchnic blood flow. On the 
basis of these studies, it has been suggested that hyperglucagonemia may 
account for approximately 30% to 40% of the splanchnic vasodilatation of 
chronic portal hypertension. Glucagon may promote vasodilatation by a dual 
mechanism: Relaxing the vascular smooth muscle and decreasing its 
sensitivity to endogenous vasoconstrictors, such as norepinephrine, 
angiotensin II, and vasopressin 28,29. The role of glucagon in the splanchnic 
hyperemia of portal hypertension provides a rationale for the use of 
somatostatin and its synthetic analogs to treat portal hypertension 30. 
Endocannabinoids :  Recent data suggest a role for endocannabinoids in 
the hyperdynamic circulation of portal hypertension 31,32. 
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Nitric oxide : Experimental studies of specific NO inhibitors have shown 
that NO is involved in the regulation of splanchnic and systemic 
hemodynamics in portal hypertensive and control animals33,34. In addition, 
NO inhibition has been shown to reverse the vascular hyporesponsiveness to 
vasoconstrictors that is characteristic of portal hypertension and is thought to 
contribute to systemic and splanchnic vasodilatation 35. The finding in 
patients with cirrhosis of increased serum and urinary concentrations of 
nitrite and nitrate, which are products of NO oxidation, also supports a role 
for NO in the genesis of the circulatory disturbances of portal hypertension 
36. The increased production of NO is due both to an increased expression 
and an increased activity of eNOS37.38. Factors likely to activate the 
constitutive NO synthase include shear stress, circulating vasoactive factors 
(e.g., ET, angiotensin II, vasopressin, and norepinephrine) and 
overexpression of the angiogenic factor vascular endothelial cell growth 
factor (VEGF) 39,40.  
Prostaglandins :   Several studies support a role for prostaglandins in the 
hyperdynamic circulation in portal hypertension 41,42,43,44.  
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Portosystemic Collateral Circulation 
           The development of portal–collateral circulation is one of the main 
complications of portal hypertension. Formation of collaterals is a complex 
process involving the opening, dilatation, and hypertrophy of preexisting 
vascular channels 45. Collaterals develop in response to the increased portal 
pressure. A minimum HVPG threshold of 10 mm Hg should be reached for 
the development of portosystemic collaterals and esophageal varices 46,47,3. 
In addition to the increased portal pressure, recent studies have shown that 
formation  of portosystemic collateral vessels in portal hypertension is 
influenced by a VEGF dependent angiogenic process and can be markedly 
attenuated by interfering with the VEGF/VEGF receptor-2 signaling 
pathway 39,40. These studies have opened a new perspective in the 
understanding of the pathophysiology of portal hypertension, with potential 
clinical relevance, because these studies indicate that manipulation of the 
VEGF may be of therapeutic value. The collateral circulation may carry as 
much as 90% of the blood entering the portal system. In this circumstance, 
the vascular resistance of these vessels becomes a major component of the 
overall resistance to portal blood flow and, therefore, may be important in 
determining portal pressure. In addition, although it was traditionally 
thought that the hyperdynamic splanchnic circulatory state associated with 
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portal hypertension was the consequence of active splanchnic vasodilatation, 
recent data suggests that the increased neovascularization in splanchnic 
organs plays an important role in allowing the increase in splanchnic blood 
inflow 40. The elements that modulate collateral resistance are not well 
known. Studies performed in perfused portosystemic collateral beds suggest 
that NO may play a role in the control of portal collateral vascular resistance 
48. This may be the mechanism by which isosorbide-5-mononitrate (IMN) 
and nitroglycerin (NTG) reduce collateral resistance in patients with 
cirrhosis. Vasoconstrictive agents (including vasopressin and nonselective β-
blockers) may significantly increase the collateral resistance. The increase in 
portal collateral resistance brought about by these agents attenuates the 
reduction in portal pressure achieved by reducing the splanchnic blood flow.  
Esophageal Varices  
           Esophageal varices are present in approximately 40% of patients with 
cirrhosis and in as many as 60% of patients with cirrhosis and ascites 49. In 
cirrhotic patients who do not have esophageal varices at initial endoscopy, 
new varices will develop at a rate of approximately 5% per year. In patients 
with small varices at initial endoscopy, progression to large varices occurs at 
a rate of 10% to 15% per year and is related predominantly to the degree of 
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liver dysfunction 50. On the other hand, improvement in liver function in 
patients with alcoholic liver disease who abstain from alcohol is associated 
with a decreased risk, and sometimes even disappearance, of varices 51. 
        Up to 25% of patients with newly diagnosed varices will bleed within 
two years. The best clinical predictor of bleeding appears to be variceal size. 
The risk of bleeding in patients with varices less than 5 mm in diameter is 
7% by two years, and the risk in patients with varices greater than 5 mm in 
diameter is 30% by two years (50). Even more important, however, is the 
HVPG because the risk of bleeding is virtually absent when the HVPG is 
below 12 mm Hg 52.  Nevertheless, measurement of HVPG is not routinely 
performed in clinical practice to assess bleeding risk. The prognosis for 
variceal bleeding in patients with cirrhosis has improved since the 1980s. 
Initial treatment is associated with cessation of bleeding in approximately 
90% of patients 50. Approximately one half of patients with a variceal bleed 
stop bleeding spontaneously because hypovolemia leads to splanchnic 
vasoconstriction, which results in a decrease in portal pressure. Excessive 
transfusions may, in fact, increase the chance of rebleeding. Active bleeding 
at endoscopy, a lower initial hematocrit value, higher serum 
aminotransferase levels, higher Child class, bacterial infection, an HVPG 
greater than 20 mm Hg, and portal vein thrombosis are associated with 
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failure to control bleeding at five days 50,53.  Of patients who have stopped 
bleeding, approximately one third will rebleed within the next six weeks. Of 
all rebleeding episodes, approximately 40% will take place within five days 
of the initial bleed. Predictors of rebleeding include active bleeding at 
emergency endoscopy, bleeding from gastric varices, hypoalbuminemia, 
renal insufficiency, and an HVPG greater than 20 mm Hg. The risk of death 
with acute variceal bleeding is 5% to 8% at one week and about 20% at six 
weeks 50.  
Gastric Varices                     
       Gastric varices typically occur in association with more advanced portal 
hypertension. Bleeding is thought to be more common in patients with 
GOV2 and IGV1 than in those with other types of gastric varices; in other 
words, bleeding is more common from fundal varices than from varices at 
the gastroesophageal junction. Whereas intraesophageal pressure is negative, 
intra-abdominal pressure is positive, and the transmural pressure gradient 
across gastric varices is smaller than that across esophageal varices. Gastric 
varices, however, tend to be larger in diameter than esophageal varices.  
            Gastric varices are supported by gastric mucosa, whereas esophageal 
varices tend to be unsupported in the lower third of the esophagus. 
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Therefore, gastric varices are likely to bleed only when they are large, as 
demonstrated in a study in which larger gastric varices (greater than 5 to 
10 mm in diameter) were more likely to bleed than smaller ones 54. Although 
gastric varices have been thought to bleed less frequently than esophageal 
varices, the bleeding rates probably are comparable if patients are matched 
for the severity of cirrhosis (CTP score).[ In contrast with esophageal 
varices, bleeding from gastric varices has been described with an HVPG less 
than 12 mm Hg 55,56. Gastric varices in continuity with esophageal varices 
may regress following treatment of the esophageal varices. When gastric 
varices persist despite obliteration of esophageal varices, the prognosis is 
poorer, probably because of the severity of liver disease.  
Anorectal varices 
         Blood from the haemorrhoidal venous plexus passes via the azygous 
superior rectal vein into the inferior mesenteric vein and thereafter into the 
portal vein. By contrast, the paired middle rectal vein and inferior rectal vein 
discharge their blood via the iliac vein into the inferior vena cava. In portal 
hypertension, anorectal varices are found in the region of the rectum, the 
anal canal and the external anal region. • Haemorrhoids are distended and 
dislocated cavernous bodies in the rectum, which have no connection to the 
portal venous system. • Although haemorrhoids and anorectal varices are 
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two different clinical pictures, it is quite possible for them to occur 
simultaneously. The frequency of anorectal varices (40 - 80%) is dependent 
upon the extent and duration of portal hypertension. The bleeding tendency 
is low (7 - 14%). However, there have also been reports of massive 
haemorrhages. 57 
MUCOSAL CHANGES IN PORTAL HYPERTENSION 
PORTAL HYPERTENSIVE GASTROPATHY (PHG) : 
       The hallmarks of the lesions in PHG are ectatic vessels in the 
mucosa and submucosa with insignificant inflammatory cellular infiltrate 59. 
Its  prevalence  among portal hypertensive patients   ranges from 7% to 41% 
60. In the largest study on the natural history of PHG , the overall prevalence 
of this condition in patients with cirrhosis was 80 %  61.  
The mechanisms involved in the pathogenesis of PHG have not been 
fully elucidated, yet chronic increase in the portal pressure is a prerequisite 
for its development 59. Several factors with varying degrees of involvement, 
are implicated in the mechanism of  PHG e.g. neurohumoral or paracrine 
substances, hypervolemia, meals, tissue hypoxia and in certain cases 
hepatocelluar insufficiency. The gastric mucosal blood flow state is   
debatable . Decrease in blood flow to the mucosa and increased blood flow 
to the submucosa, muscle, and serosal layers  have been documented in 
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PHG. Moreover , a higher hemokinetic stress in severe PHG cases than in 
mild cases or controls is proved by using endoscopic laser Doppler 
flowmetry.  
         Many trials have evaluated the portal hypertensive mucosa in relation 
to many internal and external factors. It is worth to mention the damaging 
effects proved by the decreased gastric mucosal prostaglandin E2 generation 
in PHG. Sarin et al. has  confirmed that PHG is greatly influenced by the 
severity of liver disease 62. Conversely, Primignani et al. suggests that the 
correlation is weak 61.  
         Studying the impact of variceal eradication by   sclerotherapy or 
ligation (EVS or EVL) on PHG revealed the whole spectrum of 
probabilities.   Sarin et al.   reported that EVS is incriminated in worsening 
PHG as compared to EVL. Although patients in this study were of a variable 
spectrum of liver disease (cirrhosis, fibrosis, extra-hepatic portal vein 
obstruction and Budd-Chiari cases), yet it had the most prolonged duration 
of follow up (23.2 +/- 3.4 months)  .Other studies have  flipped the coin, 
incriminating EVL as compared to EVS 62,63. While Hou et al. didn't find 
any significant difference between either of EVL and EVS on PHG 64. 
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      The identification of endoscopic lesions of PHG   allowed the 
development of a reproducible classification defining mild and severe 
pictures as well as the conduction of natural history studies 64. The 
elementary lesions in PHG are mosaic like pattern, red point lesion, cherry 
red spots and black brown spots. According to the New Italian Endoscopic 
Club, in mild PHG the gastric mucosa often looks reddened and edematous 
with a snakeskin or mosaic pattern.   Severe PHG is defined by cherry red 
spots, which are typically very friable and can actively bleed during 
endoscopy. Such changes are typically localised to the fundus or corpus of 
the stomach. There is no specific histology  nor correlation between the 
endoscopic and the histologic features in PHG. Ectasia and sclerosis of the 
wall of the mucosal capillaries and venules are common findings with  
venous congestion. Therefore, Misra et al.  has stated   that the thick  gastric 
mucosal capillary wall   is a   reliable histological marker of portal 
hypertension than dilated gastric mucosal capillaries65. 
                  Patients with PHG may present with clinically significant blood 
loss, melena, or more commonly chronic anemia. The incidence of bleeding 
is more common as chronic bleeding (12%) than   acute bleeding (2.5%). 
Bleeding related  mortality reaches 12.5% 61. Zoli et al. study has mentioned  
that  patients with severe PHG who have  severe liver  dysfunction,  are 
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liable to develop future variceal bleeding. Other studies didn't find any 
correlation of PHG to: (i)   history of upper GI bleed; (ii) size of    varices; 
(iii)  etiology of liver cirrhosis; or (iv) liver function status. The prevalence 
of PHG was found  higher in patients with esophagogastric varices (74 / 107; 
69%) compared to those with esophageal varices alone (68 / 123; 55%; P < 
0.05). A recent  study by Stewart  and Sanyal     showed  a stepwise increase 
in PHG-related bleeding risk with increasing PHG scores 66.    
    β- blockers (propranolol),somatostatin, octreotide ,  vasopressin, 
terlipressin and estrogen have been proposed for the treatment of PHG based 
on their ability to decrease gastric perfusion 67.  β- blockers are the drug of 
choice for prevention of   GI  bleeding in PHG  , with the dosage titrated up 
to achieve a resting heart rate of approximately 60 beats per minute. In 
patients who do not respond to beta-blockers, a TIPS should be placed.; 
Portosystemic shunt surgery is another alternative in the suitable candidate67. 
            Due to the lack of randomized studies , the fluctuating nature of 
PHG and possibly unreported failures, both TIPS and shunt surgery 
should be considered only as a rescue therapies for the uncommon 
patients who has repeated bleeding from PHG despite propranolol 
treatment. Liver transplantation reverses portal hypertension and 
therefore effectively treats PHG. 
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GASTRIC ANTRAL VASCULAR ECTASIA (GAVE) : 
                   GAVE ,also known as watermelon stomach , is relatively rare  . 
It is characterised by red patches or spots in either a diffuse or linear array in 
the antrum of the stomach , which can result in significant blood loss and 
leads to chronic iron deficiency anemia that is difficult to treat. Its etiology 
is  unclear. Vasoactive substances may play an important role in the etiology 
of vascular ectasia. Neuroendocrine cells containing vasoactive intestinal 
peptide and 5-hydroxtryptamine have been found close to the vessels in the 
lamina propria of resected specimens from GAVE patients .So, these 
mediators may be responsible for the vasodilatation and thus the propensity 
to bleed .GAVE in cirrhotic patients may be explained by the shunting of 
blood and altered metabolism of vasoactive substances in the presence of 
liver disease 68 . Moreover , abnormal response to mechanical antral stress is 
another factor.  
                 GAVE have  several disease association as primary biliary 
cirrhosis (PBC) , connective tissue disease,etc…More than 70% of patients 
with GAVE syndrome do not have cirrhosis or portal hypertension (PBC). 
However, in the setting of cirrhosis, GAVE syndrome can be difficult to 
differentiate from PHG.   Both conditions are diagnosed endoscopically as 
collections of discrete red spots of ectatic vessels arranged in stripes along 
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the antral rugal folds; however, the red spots of PHG appear in a background 
of  mucosal mosaic appearance, but the mucosa underlying GAVE is 
normal.  Histologically , vascular ectasia in GAVE are seen in the mucosa 
associated with fibrin thrombi ,fibrohylinosis and spindle cell proliferation 
69. Drugs of reported benefit include estrogen and progesterone 70.  The 
success of endoscopic therapies have been reported  to improve lesions and  
decrease blood requirements ,  although , such treatments are   not   effective 
in   patients with diffuse GAVE  , such modalities include cautery by Argon 
Plasma Coagulator ,heater probe ,or Yag laser .   Surgical treatment, 
including antrectomy, can cure GAVE syndrome, but in  patients with  
cirrhosis and  portal hypertension , the morbidity of surgery  may be reduced 
by reducing portal pressure 71. 
                      Gastroduodenal ulcers and gastroduodenal erosions are 
particularly frequent in cirrhotic patients, but their precise cause is unclear. 
However, the postulation that portal hypertensive mucosa is relatively 
ischemic and is liable to noxious injury may as well explain the association 
of such lesions. 
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 PORTAL HYPERTENSIVE ENTEROPATHY (PHE) : 
            Small bowel mucosa  in portal hypertension was recently 
assessed extensively. It is a recognized potential source of bleeding in portal 
hypertension. However, the frequency of its involvement is unknown.  
Nagral et al.  has  claimed  that  PHE  is  part of the spectrum of congestive 
gastroenteropathy and occurs at least as frequently as changes in the stomach 
and duodenum. In addition , its incidence doesn't correlate with the Child-
Pugh score or with prior   sclerotherapy 72 . Similar to PHG, several 
incriminating factors have been proposed including circulating hormonal 
vasodilators from intestinal origin such as glucagon, insufficiently cleared 
by the liver, as well as increased nitric oxide production. Glucagon in a dose 
sufficient to acutely elevate portal venous pressure aggravates noxious injury 
of the mucosa in rats with portal hypertension. Infusion of a portal 
hypotensive dose of somatostatin reverses these changes.  
                     Misra et al has reported    a significant dilatation in the mucosal 
vessels with thickened walls in duodenal and jejunal biopsy specimens in 
portal hypertensive patients compared to controls(67% and 71% vs 27% and 
2% respectively)73. Increased mucosal mast cell infiltration   suggests an 
inflammatory background for PHE in addition to the documented vascular 
changes.   Other important histologic features in the portal hypertensive 
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patients include edema of the lamina propria, fibromuscular proliferation, a 
decreased villous/crypt ratio, and thickened muscularis mucosae. The 
clinical implication of these changes is the increased chance of occult 
gastrointestinal blood loss 73. PHE is usually asymptomatic, Massive 
hemorrhage has only rarely been described and its management is 
controversial Gastrointestinal wall thickening is  common on contrast-
enhanced abdominal CT scans. It   involves multiple segments( commonly   
jejunum and ascending colon ). 
Protein loosing enteropathy and intestinal lymphagiectasia in portal 
hypertension drew the attention of researchers. Stanley et al.  recently 
suggested  that the mucosal congestion  may lead to protein loss in addition 
to blood loss , probably by dysfunction of the intestinal lymphatics  ,and this 
could be corrected by TIPS 74. 
         Functionally, the spectrum of portal hypertension in the 
gastrointestinal tract still extends to include altered intestinal motility with 
delayed transit, mainly in the proximal part of the small intestine, which may 
predispose to bacterial overgrowth and malabsorption. 
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PORTAL HYPERTENSIVE COLOPATHY ( PHC) : 
               Over the past few years, it has been observed that not only the 
stomach but the entire gastrointestinal tract, with its venous drainage through 
the portal venous system, is involved in patients with portal hypertension. 
Involvement of the duodenum , the small intestine , and the colon  have all 
been described. There is continuing controversy regarding information on 
the involvement of the colonic mucosa in these patients. Only a few studies, 
however, have investigated the colon in patients with portal hypertension.  
                  Colorectal mucosal lesions in patients with portal hypertension is 
termed  as portal hypertensive colopathy (PHC). These are thought to be 
important causes of lower gastrointestinal hemorrhage, although the clinical 
importance of these lesions in patients with portal hypertension  is not well 
established. The features of PHC are not well defined but include multiple 
vascular appearing lesions ( telangiectasias, cherry red spots and 
angiodysplasia like lesions), colitis- like abnormalities ( granularity, 
erythema, edema, friability ), colorectal varices, or a combination of these 
findings 75. The diagnostic criteria and clinical significance of this condition 
is confusing. This may be partially due to imprecise terminology, lack of 
uniform endoscopic descriptions, interobserver variability and the absence of 
distinctive histopathologic features.  
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Bini et al. and  Keiichi et al. proposed a classification system for describing 
portal hypertensive colopathy 76,77. 
Bini et al. classification : 
Grade 1 -   Erythema of the colonic mucosa  
Grade 2  -  Erythema of the colonic mucosa along with a mosaic-like  
                  appearance of  the mucosa 
 Grade 3 -  Vascular lesions of the colon, including cherry red spots, 
                  telangiectasias, or angiodysplasia-like lesions 
 Keiichi et al. classification : 
1. Solitary vascular ectasias  
2. Diffuse vascular ectasias 
3. Redness 
4. Blue vein 
                          Misra et al.  reported dilated tortuous mucosal capillaries 
with irregular thickening of wall, edema of lamina propria and mild chronic 
inflammatory infiltrate as the major histopathological changes seen in 
31 
 
colonic biopsies of patients with PHC 78. The histological changes have no 
correlation with the clinical or endoscopic findings, however, the thickness 
of the capillary wall is higher in patients who had undergone sclerotherapy78. 
                   According to Bini et al. the prevalence of colonic mucosal 
abnormalities in patients with cirrhosis and portal hypertension is as follows, 
colitis like abnormalities seen in 38% of patients, vascular lesions seen in 
13%, rectal varices seen in 9% and hemorrhoids seen in 46% of patients 77. 
Whereas Ganguly et al. concluded in his study that colitis like abnormalities 
seen in 6% of patients, vascular lesions seen in 52% and rectal varices seen 
in 44% of patients 79. In an another study by Misra et al. reported that colitis 
like abnormalities seen in 27% , vascular lesions seen in 49% , rectal varices 
in 40% and hemorrhoids in 36% of patients.   
                    Misra et al. also reported  that the relationship between portal 
hypertensive colopathy and anorectal varices is inverse. He proposed the 
reason for this is that the anorectal varices decompress the colonic mucosa, 
making portal hypertensive colopathy less common in patients with 
anorectal varices than in patients without these varices 78, 81.  
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              Keiichi Ito et al. concluded in his study that the prevalence of portal 
hypertensive colopathy increases as the child pugh class worsens in patients 
with cirrhosis.  Whereas Bresci et al. described in his study that the type and 
prevalence of colonic lesions in cirrhotic patients are not associated with the 
either etiology or severity of  cirrhosis. 82 
              Keiichi Ito et al. also described an interesting observation from his 
study that the prevalence of  portal hypertensive colopathy increases with 
decreases in platelet count 82. This observation was not seen in any of the 
other published series. 
             It has been reported by many of the authors 77,83,84,85 that 
sclerotherapy or band ligation of esophageal varices may promote the 
development of colonic varices and mucosal lesions; however, Misra et.al. 
reported that sclerotherapy or band ligation for esophageal varices did not 
have any significant effect on the prevalence of mucosal abnormalities in the 
colon. Later Bresci et al. also concluded in his study that the prevalence of 
colonoic mucosal abnormalities does not increase  with prior endoscopic 
treatment of esophageal varices 76. 
           In a study by El Kady et al. concluded that the severity or grading of 
esophageal varices does not correlate with prevalence of portal hypertensive 
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colopthy 86. Similarly Misra et al and Bini et al found no clear relationship 
between large esophageal varices or severity of portal hypertensive 
gastropathy and portal hypertensive colopathy 77,75. 
            Misra et al. described in his study that the features of portal 
hypertensive colopathy is more commonly seen in the left side of the colon 
75. Whereas Kozarek et al. 87 noted it to be more common in the right side 
and Bini et al. noted that the pancolonic involvement is more common 77. 
           Sarin et al. concluded that the frequency of portal hypertensive 
colopathy is nearly equal in cirrhosis, Non cirrhotic portal hypertension and 
Extrahepatic portal venous obstruction whereas the rectal varices were more 
often seen in EHPVO than NCPF and cirrhosis and also it was found to be 
larger in EHPVO than NCPF and cirrhosis 79. 
          Rectal EUS is used recently for evaluation of the anorectal region in 
portal hypertension .  Dhiman  et al .  studied changes in the venous system 
of the rectum using endoscopy and EUS in 60 patients with portal 
hypertension (cirrhotic 41, noncirrhotic 19) and 10 controls 88. Prevalence of 
rectal varices was 43.3% on endoscopy  and 75% on EUS (p < 0.0005). 
Congestive rectopathy was found in 38.3% of patients. Multiple small 
dilated vessels in the submucosa were seen in 23.3% of patients on rectal 
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EUS. The development of these vascular changes was significantly 
influenced by sclerotherapy, but not by higher grade of esophageal varices, 
the etiology of portal hypertension, or severity of liver disease.  
                The mucosal changes in PHC  may require pharmacological, 
directed endoscopic, or portal decompressive therapy , so octreotide may 
find a place in its treatment. TIPS has recently been suggested to be useful in 
the therapy of bleeding from parastomal , vascular ectasia like  lesions or 
anorectal varices in patients unresponsive to conservative therapy 83,84. 
   Most of the prospective studies and published reports which 
investigated the colonic mucosal changes in patients with liver cirrhosis and 
portal hypertension are often based on patients with overt lower 
gastrointestinal symptoms. Very few studies have investigated in 
asymptomatic patients. Therefore in our study we have evaluated the colonic 
mucosal abnormalities in liver cirrhosis and portal hypertension patients 
without any lower gastrointestinal symptoms as a screening and assessed the 
clinical significance of such lesions and its relationship with severity of liver 
failure,  grading of esophageal varices and the effect of endoscopic variceal 
ligation. 
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                                       AIM OF THE STUDY  
1. To find out the prevalence of colonic mucosal abnormalities in 
patients with cirrhosis and portal hypertension. 
2. To assess the relationship between colonic mucosal abnormalities 
and the severity of liver disease. 
3. To assess the relationship between colonic mucosal abnormalities 
and the  grading of esophageal varices. 
4. To investigate the effect of endoscopic variceal ligation of the 
esophageal varices on the colonic mucosal changes. 
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                            MATERIALS AND METHODS 
Place of study      : Department of Digestive Health and Diseases, 
          Government Peripheral hospital, Anna nagar, 
         Chennai. 
Type of study     : Prospective study. 
Period of study     : December 2008 to December 2010. 
Ethical committee    : Approval obtained. 
Consent               : Informed consent obtained from all participants 
Selection of patients : 
Inclusion criteria : 
• Age between 18 and 65 years 
• Group 1 -  30 consecutive newly diagnosed patients with  
                   cirrhosis and Portal hypertension not exposed to 
                  medical and endoscopic treatment. 
• Group 2 -  30 patients with cirrhosis and portal hypertension 
                  Who underwent atleast 1or more sessions of 
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                   endoscopic variceal Ligation for variceal  
                   obliteration. 
Exclusion criteria  : 
• Previous surgical intervention for portal hypertension 
• Patient on primary pharmacological prophylaxis for variceal bleeding 
• Coexisting cardiac disease, patients on beta blockers 
• Patients with colitis 
• Patients with chronic kidney disease 
• Hepatocellular carcinoma detected by ultrasound 
• Advanced comorbidity for endoscopy 
• Patients operated for haemorrhoids 
• Personal history of malignancy 
• Patients with primary sclerosing cholangitis 
• Patients with active G I bleed  
 
Clinical evaluation:                                                                  
                 All patients underwent a detailed clinical evaluation at entry. 
Detailed history and physical characteristics including age, gender, signs of 
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liver failure (spider angioma, palmar erythema etc.), hepatomegaly, 
splenomegaly, ascites and abdominal vein collaterals were recorded. All 
patients selected for the study underwent the following investigations; 
Blood and Stool tests: 
                  Hematological and biochemical workup included measurement 
of hemoglobin, total leukocyte count, platelet count, prothrombin time, and 
serum concentrations of bilirubin (total and conjugated), protein, albumin, 
alanine aminotransferase and aspartate aminotransferase. For each patient, 
severity of liver failure was calculated using Child-Pugh score.9 All patients 
were tested for HBsAg and antibodies to hepatitis C virus using enzyme 
immunoassays to determine the cause of liver cirrhosis. Tests for other 
causes of cirrhosis (serum ceruloplasmin and slit lamp examination for 
Wilson’s disease, tests for autoantibodies for autoimmune liver disease, iron 
studies for hemochromatosis) were carried out only if there was a suggestive 
clinical clue. In patients with ascites, ascitic fluid was tapped under aseptic 
precautions and ascitic fluid albumin and serum-ascites albumin gradients 
were measured to document high SAAG ascites. All patients stool was 
examined for ova, cyst and occult blood. 
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Ultrasound Doppler:  
                  All patients underwent ultrasonography after over night fast and 
the following details were recorded: maximum vertical span of the liver; 
nodularity of liver surface; SOL in liver; spleen size; diameter of the portal 
and splenic veins; presence of portal-systemic collaterals; and presence of 
ascites.  
Endoscopic evaluation:  
      All patients underwent upper gastrointestinal endoscopy for 
assessment of esophageal and gastric varices using video gastroscope 
(PENTAX) with in 2-3 days of admission. If esophageal varices were 
present, their size was graded as I-IV, using the Paquet grading system94. 
Presence of gastric varices, portal hypertensive gastropathy, duodenopathy 
and were recorded in all the patients. Gastric varices were classified 
according to Sarin classification.93  
                Full length colonoscopic examination of the lower gastrointestinal 
tract was performed (PENTAX Video Colonoscope) in each patient after 
adequate bowel preparation using polyethylene glycol electrolyte solution 
completed atleast 6 hours prior to the study. During colonoscopy, a careful 
search was made for hemorrhoids, anorectal varices, colonic varices and 
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mucosal lesions of portal hypertensive colopathy. Briefly, hemorrhoids were 
defined as large venous structures at or just proximal to the anus. Anorectal 
varices were defined as bluish or gray, distended, tortuous or saccular veins 
seen well above the anal margin, extending into the rectum. If such a lesion 
was seen above the rectum it was termed a colonic varix. Portal hypertensive 
colopathv was defined as diffuse hyperemia and edema resembling chronic 
colitis, lesions such as spider angiomas, patchy localized hyperemic lesions, 
or severe hyperemia with an acute colitis-like picture with spontaneous 
bleeding from the colonic mucosa78. 
                Endoscopic Variceal Ligation was performed using Variclear 
Band Ligator by Wilson Cook  Medicals. Six bands were placed in one 
session. EVL was performed every fortnightly. All the patients in group 2 
underwent atleast two sessions of EVL. None of the patients received beta 
blockers during EVL. Colonoscopy was performed six weeks after the last 
EVL session. 
              Diagnosis of cirrhosis was based on clinical, biochemical, and 
ultrasonographic findings. All patients were followed up for a period of 
atleast six months to one year.  
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 STATISTICAL ANALYSIS : 
                    Statistical analyses were carried out to compare continuous 
variables using Student’s t test. Chi−squared analysis was used to evaluate 
categorical variables. A two−tailed P value of <0.05 was considered 
statistically significant. All analyses were performed using SPSS 16.0 (SPSS 
Inc. Chicago, IL). 
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                                      RESULTS 
                 The total number of patients included in this study was 30 in 
group 1 and 30 in group 2. 
TABLE 1 : Age Distribution 
Age Group 1 Group 2 
Range 22 – 65 32 – 65 
Mean 47.57 47.53 
Standard deviation 11.43 11.56 
 
                 The mean age of the patients in group 1 was 47.57 ( range 22 – 65 
yr) and in group 2 was 47.53 ( range 32 – 65 yr) 
TABLE 2 :  Sex Distribution 
Sex Group 1 Group 2 
Male 24 (80%) 21 (70%) 
Female 6 (20%) 9 (30%) 
Total 30 30 
P value = 0.371 
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                Out of 30 patients in group 1, 24 were males and 6 were females 
whereas in group 2, 21 were males and 9 were females. There was no 
statistically significant difference between the two groups. 
TABLE 3 :  Esophageal Variceal Grading in Group 1 
Esophageal variceal grade Group 1 
Grade 1 0 
Grade 2 13 (43.3%) 
Grade 3 15 (50%) 
Grade 4 2 (6.7%) 
Total 30 
               Out of 30 patients in group 1, 13 patients had grade 2 varices, 15 
had grade 3 varices and 2 patients had grade 4 varices. 
TABLE 4 :  CTP Class Distribution in Group 1 
CTP Group 1 Group 2 
A 6 (20%) 6 (20%) 
B 14 (46.7%) 11 (36.7%) 
C 10 (33.3%) 13 (43.3%) 
Total 30 30 
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                 Out of 30 patients in group 1, 6 belonged to CTP class A, 14 
belonged to CTP class B and 10 belonged to CTP class C. 
 
TABLE 5 :  Etiology Distribution  
 
ETIOLOGY Group 1 Group 2 
Ethanol 20 (66.7%) 17 (61.7%) 
HBV 3 (10%) 5 (16.7%) 
HCV 1 (3.3%) 0 
Auto immune 2 (6.7%) 3 (10%) 
Wilson 1 (3.3%) 0 
Cryptogenic 3 (10%) 5 (16.7%) 
Total 30 30 
P value = 0.632 
             Majority of patients in both the groups, the etiology for chronic liver 
disease was due to ethanol ( 66.7% in group 1 and 61.7% in group 2 ). 
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TABLE 6 :  Hemorrhoids 
Hemorrhoids Group 1 Group 2 
Present 6   ( 20%) 8   (26.7%) 
Absent 24 (80%) 22 (73.3%) 
Total 30 30 
P value = 0.542 
                In group 1, 6 out of 30 patients had hemorrhoids ( 20%) whereas 
in group 2, 8 out of 30 patients had hemorrhoids (26.7%). There was no 
statistically significant difference between the two groups. Hence prior 
variceal obliteration by endoscopic variceal banding did not increase the 
prevalence of hemorrhoids in our study. 
 
TABLE 7 :  Rectal Varix 
Rectal varix Group 1 Group 2 
Present 3 (10%) 3 (10%) 
Absent 27 (90%) 27 (90%) 
Total 30 30 
P value = 1.00 
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               In both group 1 and 2, 3 patients had rectal varix (10%). There was 
no statistically significant difference between the two groups. Therefore, 
endoscopic variceal banding did not increase the development of rectal varix 
in our study. 
TABLE 8 :  Portal Hypertensive Colopathy 
PHC Group 1 Group 2 
Present 15 (50%) 17 (56.7%) 
Absent 15 (50%) 13 (43.3%) 
Total 30 30 
P value = 0.605 
              In group 1, 15 out of 30 patients showed colonoscopic features of 
portal hypertensive colopathy ( 50%)  whereas in group 2, 17 out of 30 
patients had features of portal hypertensive colopathy (56.7%) which was 
not statistically significant. 
              Therefore, prior variceal obliteration by endoscopic variceal 
ligation did not increase the prevalence of portal hypertensive colopathy in 
our study. 
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TABLE 9 : Correlation Between Esophageal Variceal Grading and 
                    PHC in  Group 1 
 
PHC Esophageal Variceal Grading Total 
Grade 1 Grade 2 Grade 3 Grade 4 
Present 0 2  (13.3%) 11 (73.3%) 2  (100%) 15 
Absent 0 11(73.3%) 4  (26.7%) 0 15 
Total 0 13 15 2 30 
P value = 0.03 
 
              In group 1, 2 out of 13 patients with grade 2 varices, 11 out of 15 
patients with grade 3 varices and 2 out of 2 patients with grade 4 varices had 
portal hypertensive colopathy.  
              Therefore, the chances of patient having portal hypertensive 
colopathy increases as the increase in esophageal variceal grading. 
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TABLE 10 : Correlation Between PHC and CTP Class in Group 1 
 
 
PHC 
CTP class  
Total A B C 
Present 1 (16.6%) 6 (42.8%) 8 (80.9%) 15 
Absent 5(83.4%) 8(57.2%) 2(19.1%) 15 
Total 6 14 10 30 
P value = 0.043 
 
                       In group 1, 1 out of 6 patients in CTP class A (16.6%), 6 out 
of 14 in class B (42.8%)  and 8 out 10 in class C (80.9%) showed showed 
features of portal hypertensive colopathy in colonoscopy which was 
statistically significant. 
                       Therefore, the prevalence of portal hypertensive colpathy 
increases as the CTP class worsens. 
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TABLE 11 :  PHC Site Distribution in Group 1 
PHC Group 1 Group 2 
Left colon 8  (53.3%) 10 (58.8%) 
Right colon 3  (20%) 2  (11.7%) 
Diffuse 4  (26.7%) 5  (29.4%) 
Total 15 17 
P value = 0.532 
                Majority of patients in both the groups ( 53.3% in group 1 and 
58.8% in group 2) showed predominant left sided colonic I involvement. 
There was no statistically significant difference between the two groups. 
TABLE 12 :  Specific Lesions in PHC 
Type of  lesion Group 1 Group 2 
Erythema alone 6 (40%) 8 (47%) 
Colitis like 5 (33.3%) 4 (23.5%) 
Vascular lesions 4 (26.6%) 5 (29.5%) 
Total 15 17 
P value = 0.542 
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                Majority of patients in both the groups showed erythema alone ( 
40%) in group 1 and 47% in group 2). There was no statistically significant 
difference between the two groups.               
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                                       DISCUSSION 
Prevalence of portal hypertensive colopathy : 
              In our study, the prevalence of portal hypertensive colopathy (PHC) 
in group 1 (treatment naïve ) was 50% and in group 2 ( post EVL ) was 
56.7% which is more or less similar to the previously published studies. 
               In a prospective study done by Bresci et al. 76 , 85 patients with 
cirrhosis and portal hypertension with no other significant disease underwent 
colonoscopy to evaluate the prevalence of portal hypertensive colopathy, 
and concluded that the prevalence of portal hypertensive colopathy in 
patients not exposed to endoscopic treatment was 54%  and in patients 
exposed to endoscopic treatment like Enodoscopic Sclerotherapy (EST) or 
Endoscopic Variceal Ligation (EVL) for variceal bleed was 53% which was 
not statistically significant. 
               Similarly, Misra et al.78 did a prospective study in 60 patients with 
cirrhosis and portal hypertension before and 6 weeks after EVL and 
obliteration of varices for variceal bleed and they concluded that the 
prevalence of portal hypertensive colopathy was 57% before EVL and 57% 
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after EVL and there was no statistically significant difference between the 
groups. 
            In other prospective studies by Ghosal et al.89 and  Kady et al.86 also 
showed in their studies that there was no relation between the occurrence of  
PHC and prior variceal obliteration by EVL. 
          To the best of our knowledge, most of the previously published series 
concluded that there was no relation between the prevalence of PHC and 
endoscopic variceal obliteration with the exception of only one retrospective 
study by Bini et al.77 in 437 patients with cirrhosis and portal hypertension 
which showed that the prevalence of  PHC increases with prior EVL for 
variceal obliteration. 
Comparison of prevalence of PHC in various published studies before 
EVL/ EST 
Study No. of patients Prevalence of PHC 
Bini et al.77 437 49% 
Misra et al.78 60 57% 
Keiichi et al.82 47 66% 
N.EL.Kady et al.86 40 72.5% 
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Bresci et al.76 85 54% 
Present study 30 50% 
 
Prevalence of Rectal Varix : 
             In our study, the prevalence of rectal varix in both group 1 ( 
treatment naïve ) and group 2 ( post EVL ) was 10%. There was no 
statistically significant  difference observed between the two groups.  
            Misra et al. 78did a prospective study in 60 patients with cirrhosis and 
portal hypertension before and after EVL for variceal bleed and they 
concluded that the prevalence of rectal varix was 40% in both the situation 
which was not statistically significant. 
             In a prospective study conducted by Tam et al.84 in 75 patients with 
cirrhosis and portal hypertension ( more than 80% were HBV or HCV 
positive ), they concluded that the prevalence of rectal varix was 16%. 
          In an another prospective study by Ghosal et al.89 41 patients with 
cirrhosis and portal hypertension were subjected to colonoscopic 
examination of the lower gastrointestinal tract and concluded that the 
prevalence of rectal varix in these patients was 36%. They also concluded 
that the presence of rectal varix rather than portal hypertensive colopathy 
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correlates with the occurrence of hematochzia  and none of the parameters 
like CTP class, esophageal variceal eradication by EST with or without EVL 
predicted the occurrence of rectal varices as well as portal hypertensive 
colopathy. 
         Surprisingly, in an another prospective study done by Goenka et al.90  
they concluded that the frequency of rectal varix in 75 patients with cirrhosis 
and portal hypertension was as high as 89%. 
 
Comparison of prevalence of rectal varix in various published studies 
Study No. of patients Prevalence of rectal 
varix 
Tam et al.84 75 16% 
Ghosal et al.89 41 36% 
Kozarek et al.87 20 25% 
Goenka et al.90 75 89% 
Ganguly et al.79 50 44% 
Misra et al.78 60 40% 
Bresci et al.76 85 34% 
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Present study 30 10% 
 
Prevalence of hemorrhoids : 
                     In our study, the prevalence of hemorrhoids in group 1 ( 
treatment naïve ) and group 2 ( post EVL ) was 20% and 26.7% respectively. 
There was no statistical difference observed between the two groups. The 
prevalence of hemorrhoids in adult general population is 10% to 25%.95 
 
                    In a prospective study done by Bresci et al.76  ,  85 patients with 
cirrhosis and portal hypertension with no other significant disease underwent 
colonoscopy to evaluate the prevalence of hemorrhoids, and concluded that 
the prevalence of hemorrhoids was surprisingly as high as 70%. 
 
                  Misra et al did a prospective study in 60 patients with cirrhosis 
and portal hypertension  before and 6 weeks after EVL therapy for variceal 
obliteration and reported that the prevalence of hemorrhoids was 37%  
before EVL and 37% after EVL therapy. They finally concluded that EVL 
had no significant effect on the frequency of hemorrhoids78.   
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Comparison of prevalence of hemorrhoids in various published series 
                              
Study Group No. of patients Prevalence of 
hemorrhoids 
Bresci et al.76 85 70% 
Misra et al.78 60 37% 
 Goenka et al.90 75 41% 
Ghosal et al.89 41 22% 
Present study 30 20% 
 
                    In contrast  to the other published series, the lower frequency of 
rectal varices and hemorrhoids in our study might be explained by 
differences in the patient populations studied, interobserevr variability 
among endoscopists or differences in indications of colonoscopy. Most if not 
all the above mentioned studies have done colonoscopy in patients with 
overt lower gastrointestinal symptoms whereas in our study, colonoscopy 
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was done as a screening test in patients with cirrhosis and portal 
hypertension without overt lower gastrointestinal blood loss.  
 
Comparison of colonic mucosal abnormalities between the two groups 
 
Study group 
 
Findings 
Group 1 
( treatment 
naive) 
Group 2 
( post EVL) 
 
P value 
Misra et al.78  
PHC 
 
57% 57%  
 
 
Not   
significant 
Bresci etal.76 54% 53% 
Present study 50% 56.7% 
Misra et al.78  
Rectal varix 
 
40% 40% 
Bresci et al.76 34% 28% 
Present study 10% 10% 
Misra et al.78  
Hemorrhoids
37% 37% 
Present study 20% 26.7% 
 
               It appears that following EVL, the colonic mucosa and anorectal 
varices escape the effects of variceal obliteration since they are furthest from 
the esophageal varices and the brunt of the congestion is borne by the 
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adjacent gastric mucosa resulting in increase in the occurrence of portal 
hypertensive gastropathy as documented by previously published studies. 
None of the patients in both the groups developed overt lower G I bleeding 
during the follow up. 
Correlation of  PHC and CTP class :  
              In our study, 16.6% of patients in CTP class A, 42.8% of patients in 
CTP class B and 80% of patients in CTP class C had  Portal Hypertensive 
Colopathy. 
             In contrast to previously published studies by Kozarek et al87, 
Ganguly et al79, and Bresci et al76, our study demonstrated that the 
prevalence of  PHC increased with worsening of  CTP class which was 
statistically significant with a p value of 0.043. 
            Similar to our study, Keiichi et al, Kady et al86 and Bini et al77  
showed in their studies that the prevalence of PHC increases with worsening 
of liver failure as indicated  by CTP class.  
Correlation of PHC and Esophageal Variceal Grading : 
             In our study, 13.3% of patients with grade 2 esophageal varices, 
73.3% of patients with grade 3 varices and 100% of patients with grade 4 
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varices had PHC. Therefore, our study demonstrated that the chances 
developing  PHC increases with increasing size of the esophageal varices 
which was statistically significant with a p value of 0.03. 
            Almost all the previously published studies ( N.EL.Kady et al86, 
Keiichi et al82 and Ghosal et al.89)which assessed the relationship between 
PHC and esophageal variceal grading showed that there was no relation 
between the occurrence of PHC and esophageal variceal grading with the 
exception of only one prospective study by Misra et al. which showed that 
the incidence of PHC was higher in patients with larger esophageal varices. 
PHC and site predilection : 
             In our study, more than 50% of the patients in both the groups 
showed predominant left sided colonic involvement which is similar to the 
study published by Misra et al78. Whereas in a retrospective study by Bini et 
al.77 showed 74% of the patients showed diffuse colonic involvement. 
            In an another prospective study by Kozarek et al.87 right colonic 
involvement was more common than the left colon. 
Colonic varices : 
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           In our study, none of the patients in both the groups had colonic 
varices. Similar to our study, Misra et al.78 and Naveau et al91 also noted that 
none of the patients had colonic varices  in their study cohort of  50 patients 
and 100 patients respectively.   In an another study by Ganguly et al.79 
colonic varices were noted in only one out of 50 patients studied. 
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                                          CONCLUSION 
 
1. The prevalence of portal hypertensive colopathy, rectal varix and 
hemorrhoids  in patients with cirrhosis and portal hypertension was 
50%, 10% and 20% respectively. 
 
2. The prevalence of portal hypertensive colopathy in patients with 
cirrhosis and portal hypertension increases with worsening of Child 
Pugh Turcotte score and increasing grading of esophageal varices. 
 
 
3. Esophageal variceal obliteration by endoscopic variceal ligation did 
not influence the occurrence of any of the colonic mucosal 
abnormalities in patients with cirrhosis and portal hypertension. 
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    Fig 1 : Rectal Varices 
 
 
  Fig 2 : Angiodysplasia like lesion 
Fig 3 : Patchy erythema 
 
Fig 4 : Hemorrhoids 
 
HEMORR   R.VARIX     PHC
1 44 1 1 3 2 12 0 1 1 0 0 ETHANOL
2 40 1 3 3 4 6 0 1 0 0 1 ETHANOL
3 39 1 2 3 2 15 0 1 0 0 1 ETHANOL
4 65 2 1 3 4 10 0 0 0 1 0 CRYPT
5 46 1 3 3 2 15 0 0 0 0 1 ETHANOL
6 44 1 3 3 3 8 0 1 0 0 0 ETHANOL
7 64 2 3 4 4 15 0 1 0 0 1 CRYPT
8 65 1 1 3 3 8 0 1 0 0 1 ETHANOL
9 40 1 2 3 3 10 0 0 0 0 1 ETHANOL
10 65 1 3 3 2 6 0 0 0 0 1 HCV
11 38 2 1 3 4 12 1 1 0 0 0 AIH
12 65 1 2 3 4 15 0 1 0 0 1 ETHANOL
13 45 1 1 2 2 8 1 0 0 0 0 ETHANOL
14 52 1 3 2 2 10 0 1 0 0 1 HBV
15 52 1 2 3 2 8 0 0 0 0 1 ETHANOL
16 30 1 1 2 2 6 0 1 0 0 0 ETHANOL
17 54 1 2 3 2 5 0 0 0 0 1 ETHANOL
18 44 1 3 2 3 6 0 0 0 1 0 ETHANOL
19 43 1 2 2 3 8 0 0 0 0 1 HBV
20 48 1 3 2 2 5 1 0 0 1 0 HBV
21 30 1 2 2 2 6 0 0 1 0 0 ETHANOL
22 60 1 3 3 2 8 0 0 1 0 1 ETHANOL
23 49 1 2 2 2 10 1 0 0 0 0 ETHANOL
24 22 2 2 2 2 6 0 0 0 0 0 WILSONS
25 38 1 2 3 2 8 0 0 0 0 1 ETHANOL
26 45 1 2 2 2 8 0 0 1 0 0 ETHANOL
27 49 1 2 2 3 8 1 0 0 0 0 ETHANOL
28 65 2 3 4 2 8 0 0 0 0 1 CRYPT
29 42 1 2 2 2 6 0 0 1 0 0 ETHANOL
30 44 2 2 2 3 6 0 0 1 0 0 AIH
SEXAGES.NO ETIOLOGYOV.GRCTP G.V PHGLENGTH                COLONOSCOPYCOL
                                             Proforma                                             Case No :  
                                              
                                                                                                                             
 
Name :                                                        DDHD No : 
 
Age :                                                           IP No : 
 
Sex :                                                            VOGD No : 
 
Occupation :                                                Address : 
 
Symptoms & Duration : 
 
Abdominal distention                             Leg swelling                           Jaundice 
 
Melena / hemetemesis                            Vomiting                                Bleeding tendencies 
 
Altered sensorium                                   LOW                                       LOA 
 
Lethargy                                                  Decreased urine output 
 
Past history : 
 
Similar episodes                                     Jaundice                                  Surgery 
 
Blood transfusion                                   Tattooing                                Drug abuse 
 
Native drugs                                            P.TB                                      DM 
 
SHT                                                         IHD/BA  
 
Personal history : 
 
Marital status :                                     Siblings                                      Children 
 
Smoking                                               Quantity                                    Duration 
 
Alcohol                                                 Quantity                                    Duration 
 
High risk behavior                                
 
IV Drug abuse                                       Diet and Medications 
 
Menstrual history :                                 Obstetric history : 
 
Examination : 
 
Ht :                                             Wt :                                          BMI : 
 
Pallor                                         Icterus                                      Pedal edema 
 
Clubbing                                   Cyanosis                                   LN 
 
Spider  naevi                             Scratch marks                           Palmar erythema 
 
Parotid                                      Gynacomastia                            KF ring 
 
Testicular atrophy :                   Other signs: 
 
Flapping tremor                         PR:            RR :                        BP: 
 
P/A : 
 
Distension                                 Dilated veins                            Scar/ Sinus 
 
Ascites                                      Liver span                                 Spleen 
 
Per rectal exam  
 
CVS                                          RS                                             CNS 
 
Investigations : 
 
Hb :                                          Tc :                                             Dc : 
 
ESR :                                        Platelet count :                            BT / CT 
 
RBS :                                       Urea :                                            Creatinine : 
 
P.smear :                                 Prothrombin time ;                         INR 
 
T.bil:                                         Direct :                                         Indirect :                     
 
SGOT :                                      SGPT :                                         SAP : 
 
T.Protein :                                Albumin :                                      Globulin 
 
A/G : 
 
HbsAg :                                   Anti Hcv :                                      S.Ceruloplasmin : 
 
ANA :                                      Anti Sm Ab :                                  AMA : 
 
Anti LKM Ab :                        24 hour Urine Copper : 
 
Ascitic fluid : 
 
T.Protein :                               Albumin :                                         Cell count : 
 
Cytology :                                SAAG ratio : 
 
Ultrasound color doppler : 
 
Liver size :                              Texure/ Nodule : 
 
Spleen size :                              Collaterals : 
 
OGD : 
                                               
Esophageal varices :  
 
Grade :                                   No of Columns :                                         Length : 
 
Red Signs :                             Gastric Varices :                                         PHG : 
 
PHD :                                  
 
Liver biopsy :                                                                        
 
EVL :  
 
Child pugh score :  
 
 
Colonoscopy: 
 
Erythema :                       colitis like :                           vascular lesions : 
 
Rectal varix :                   hemorrhoids :                       colonic varix : 
 
Others : 
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